Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).
Official Title
An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Adults with Hypertrophic Cardiomyopathy
Quick Facts
Study Start:2024-04-11
Study Completion:2026-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
University of California, San Francisco
San Francisco, California, 94143
United States
Stanford University Hospital / Stanford Health Care
Stanford, California, 94305
United States
James A. Haley Veterans' Hospital
Tampa, Florida, 33612
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Brigham and Womens Hospital
Boston, Massachusetts, 02115
United States
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
United States
North Shore University Hospital
Manhasset, New York, 11030
United States
NYU Langone Health Medical Center - HCM Program Office
New York, New York, 10016
United States
The Lindner Research Center at Christ Hospital
Cincinnati, Ohio, 45219
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States
Oregon Health & Science University (OHSU)
Portland, Oregon, 97239
United States
Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)
Philadelphia, Pennsylvania, 19104
United States
Virginia Mason Medical Center
Seattle, Washington, 98101
United States
Collaborators and Investigators
Sponsor: Edgewise Therapeutics, Inc.
- Medical Director, STUDY_DIRECTOR, Edgewise Therapeutics, Inc.
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2024-04-11
Study Completion Date2026-03
Study Record Updates
Study Start Date2024-04-11
Study Completion Date2026-03
Terms related to this study
Additional Relevant MeSH Terms
- Hypertrophic Cardiomyopathy